This article is more than 5 years old. Information may no longer be current.

Alcon licenses anti-infective compounds for eye, ear and sinus

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT WORTH, Texas — Alcon Inc. signed a collaborative and license agreement with NovaCal Pharmaceuticals Inc. to develop and commercialize NovaCal's Aganocide compounds for treating eye, ear and sinus infections, the companies announced.

Under the agreement, Alcon will also be responsible for all clinical development costs and will make an upfront payment to NovaCal. Alcon will be responsible for royalty payments and ongoing payments, based on development milestones and product approvals.

NovaCal retains the rights to the Aganocide compounds for other therapeutic indications, according to a press release.